Overview

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Status:
Completed

Trial end date:
2019-07-26

Target enrollment:

Participant gender:

Summary

To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Aerie Pharmaceuticals

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions